


FORM PTO-1449 (Modified)				U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-07083		Serial No.: 10/630,070	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR § 1.98(b))						Applicant: David R. Milich <i>et al.</i>			
						Filing Date: 07/30/2003		Group Art Unit:	
U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee		Class	Subclass	Filing Date	
	1	6,518,014	2/11/03	Seifer <i>et al.</i>					
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS									
		Document Number	Publication Date	Country / Patent Office		Class	Subclass	Translation	
								Yes	No
mm	2	WO/0198333 A2	12/27/01	PCT					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)									
mm	3	Birkett, U.S. Patent Application No. 20030202982, published 10/30/03							
	4	Birkett, U.S. Patent Application No. 20030185858, published 10/2/03							
	5	Zavala <i>et al.</i> , U.S. Patent Application No. 20030185854, published 10/2/03							
	6	Birkett, U.S. Patent Application No. 20030175863, published 9/18/03							
	7	Birkett, U.S. Patent Application No. 20030138769, published 7/24/03							
	8	Birkett, U.S. Patent Application No. 20030054337, published 3/20/03							
	9	Brown <i>et al.</i> , U.S. Patent Application No. 20030175296, published 9/18/03							
	10	Page <i>et al.</i> , U.S. Patent Application No. 20030198645, published 10/23/03							
Examiner: <i>m.m. Law</i>						Date Considered: <i>Dec. 04, 2004</i>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1476 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR § 1.98(b)) (Additional Sheets If Necessary)		Applicant: David R. Milich <i>et al.</i>	
		Filing Date: 07/30/2003	Group Art Unit: 1645
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)			
mm	1	Chang <i>et al.</i> , "Phenotypic Mixing between Different Hepadnavirus Nucleocapsid Proteins Reveals C Protein Dimerization To Be <i>cis</i> Preferential," (1994) J. Virol. 5225-5231	
Examiner: <i>m. m. f.</i>		Date Considered: <i>Dec. 01, 2004</i>	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-144
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: VACCINE-07083

Serial No.: 10/630,070

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: David R. Milich *et al.*

(37 CFR § 1.98(b))

Filing Date: 07/30/2003

Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
mm 	1	4,683,195	7/28/87	Mullis <i>et al.</i>	_____	_____	
	2	4,683,202	7/28/87	Mullis	_____	_____	
	3	4,965,188	10/23/90	Mullis <i>et al.</i>	_____	_____	
	4	6,602,705	8/5/03	Barnett <i>et al.</i>	_____	_____	
	5	6,406,705	6/18/02	Davis <i>et al.</i>	_____	_____	
	6	6,231,864	5/15/01	Birkett	_____	_____	
	7	4,599,230	7/8/86	Milich <i>et al.</i>	_____	_____	
	8	4,599,231	7/8/86	Milich <i>et al.</i>	_____	_____	
	9	4,683,136	7/8/87	Milich <i>et al.</i>	_____	_____	
	10	5,726,011	3/10/98	Milich <i>et al.</i>	_____	_____	
	11	4,818,527	4/4/89	Thornton <i>et al.</i>	_____	_____	
	12	4,882,145	11/21/89	Thornton <i>et al.</i>	_____	_____	
	13	5,143,726	9/1/92	Thornton <i>et al.</i>	_____	_____	

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
mm	14	WO 02/13765	12/21/02	PCT	_____	_____		
I	15	WO 01/98333 A2	12/27/01	PCT	_____	_____		

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

mm	16	Pumpens and Grens (2001) "HBV Core Particles as a Carrier for B Cell/T Cell Epitopes," <i>Intervirolgy</i> 44:98-114
	17	Jegerlehner <i>et al.</i> "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," (2002) <i>Vaccine</i> 20:3104
	18	Anderson and Young, Quantitative Filter Hybridization, in <i>Nucleic Acid Hybridization</i> [1985]
	19	Smith and Waterman (1981) "Comparison of Biosequences," <i>Adv. Appl. Math.</i> 2: 482-489
	20	Needleman and Wunsch (1970) "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," <i>J. Mol. Biol.</i> 48: 443-453 ✓
	21	Pearson and Lipman (1988) "Improved tools for biological sequence comparison," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 85:2444 ✓
	22	Sambrook <i>et al.</i> , <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Press, NY, pp 9.31-9.58, 1989
	23	Sambrook, <i>et al.</i> , <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Press, NY, pp 7.39-7.52, 1989
	24	GenBank Accession No. NKVLC2 printed 7/16/99
	25	GenBank Accession No. NP_040993 printed 12/8/02

Examiner:

Date Considered:

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR § 1.98(b))				Applicant: David R. Milich <i>et al.</i>	
				Filing Date: 07/30/2003	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
mm	26	Winter and Milstein (1991) "Man-made antibodies," Nature 349:293-299			
	27	Böttcher <i>et al.</i> (1997) "Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy," Nature 386:88-91			
	28	Conway <i>et al.</i> (1997) "Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy," Nature 386:91-94			
	29	Salfeld <i>et al.</i> (1989) "Antigenic Determinants and Functional Domains in Core Antigen and e Antigen from Hepatitis B Virus," J Virol. 63:798-808			
	30	Schodel <i>et al.</i> (1992) "The Position of Heterologous Epitopes Inserted in Hepatitis B Virus Core Particles Determines Their Immunogenicity," J Virol. 66:106-114			
	31	Milich <i>et al.</i> (1995) "The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety," Ann NY Acad Sci. 754:187-201			
	32	Pumpens <i>et al.</i> (1995) "Hepatitis B Virus Core Particles as Epitope Carriers," Intervirology 38:63-74			
	33	Clarke <i>et al.</i> (1987) "Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein," Nature 330:381-384			
	34	Schodel <i>et al.</i> (1994) "Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes," J Exp Med. 180:1037-1046			
	35	Schodel <i>et al.</i> "Immunization with Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Antigen Epitopes Protects Mice Against <i>Plasmodium yoelii</i> Challenge," (1997) Behring Inst Mitt. 114-119			
	36	Milich <i>et al.</i> (1997) "Role of B cells in antigen presentation of the hepatitis B core," Proc Natl Acad Sci USA 94:14648-14653			
	37	Kratz <i>et al.</i> (1999) "Native display of complete foreign protein domains on the surface of hepatitis B virus capsids," Proc Natl Acad Sci USA 96:1915-1920			
	38	Chen <i>et al.</i> (2000) "Nondeletional T-Cell Receptor Transgenic Mice: Model for the CD4+ T-Cell Repertoire in Chronic Hepatitis B Virus Infection," J. Virol. 74:7587-7599			
	39	Lazdina <i>et al.</i> (2001) "Molecular Basis for the Interaction of the Hepatitis B Virus Core Antigen with the Surface Immunoglobulin Receptor on Naive B Cells," J Virol. 75:6367-6374			
	40	Cao <i>et al.</i> (2001) "Hepatitis B Virus Core Antigen Binds and Activates Naive Human B Cells In Vivo: Studies with a Human PBL-NOD/SCID Mouse Model," J Virol. 75:6359-6366			
	41	Anttila <i>et al.</i> (1998) "Avidity of IgG for <i>Streptococcus pneumoniae</i> Type 6B and 23F Polysaccharides in Infants Primed with Pneumococcal Conjugates and Boosted with Polysaccharide or Conjugate Vaccines," J Infect Dis. 177:1614-1621			
	42	Arad <i>et al.</i> (2000) "Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation," Nat Med. 6:414-421			
	43	Visvanathan <i>et al.</i> (2001) "Inhibition of Bacterial Superantigens by Peptides and Antibodies," Infect Immunol. 69:875-884			
	44	DeVelasco <i>et al.</i> (1994) "Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines," Vaccine 12:1419-1422			
	45	Koletzki <i>et al.</i> (1997) "Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments," J Gen Virol. 78:2049-2053			
	46	Smiley and Minion (1993) "Enhanced readthrough of opal (UGA) stop codons and production of <i>Mycoplasma pneumoniae</i> P1 epitopes in <i>Escherichia coli</i> ," Gene 134:33-40			
	47	GenBank Accession No. NM 009778 printed April 2003			
	48	Dempsey <i>et al.</i> (1996) "C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity," Science 271:348-350			
	49	Tedder <i>et al.</i> (1994) "The CD19/CD21 signal transduction complex of B lymphocytes," Immunol Today 15:437-442			
	50	GenBank Accession No. X65453 printed April 2001			
	51	Morris <i>et al.</i> (1999) "Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD40L (CD154)," J. Biol. Chem. 274:418-423			
	52	Mackay and Browning (2002) "Baff: A Fundamental Survival Factor for B Cells," Nature Reviews Immunology 2:465-475			
	53	GenBank Accession No. NM 008479 printed April 2003			
Examiner:			Date Considered:		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: VACCINE-07083

Serial No.: 10/630,070

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: David R. Milich *et al.*

(37 CFR § 1.98(b))

Filing Date: 07/30/2003

Group Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

mm	54	El mir and Triebel (2000) "A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens," J. Immunol 164:5583-5589
	55	Krieg <i>et al.</i> (1995) "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546-549
	56	Davis <i>et al.</i> (1998) "CpG DNA is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen," J. Immunol. 160:870-876
	57	Fouet <i>et al.</i> (1999) "Bacillus anthracis surface: capsule and S-layer," J Appl Microbiol. 87:251-255
	58	Paoletti <i>et al.</i> (2002) "Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen," Vaccine 20:370-376
	59	Wang <i>et al.</i> (2003) "Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling," Vaccine 21:1112-1117
	60	Bittle <i>et al.</i> (1982) "Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence," Nature 298:30-33
	61	Van Lierop <i>et al.</i> (1992) "Proliferative lymphocyte responses to foot-and-mouth disease virus and three FMDV peptides after vaccination and immunization with these peptides in cattle," Immunol. 75:406-413
	62	Wong <i>et al.</i> (2000) "Plasmids Encoding Foot-and-Mouth Disease Virus VP1 Epitopes Elicited Immune Responses in Mice and Swine and protected Swine against Viral Infection," Virol. 278:27-35
	63	Neiryneck <i>et al.</i> (1999) "A universal influenza A vaccine based on the extracellular domain of the M2 protein," Nat Med. 5:1157-1163
	64	Heinen <i>et al.</i> (2002) "Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleotprotein fusion protein exacerbates disease after challenge with influenza A virus," J. Gen. Virol. 83:1851-1859
	65	Pekosz and Lamb (1999) "Cell Surface Expression of Biologically Active Influenza C Virus HEF Glycoprotein Expressed from cDNA," J Virol. 73:8808-8812
	66	Hughey <i>et al.</i> (1995) "Effects of Antibody to the Influenza A Virus M2 Protein on M2 Surface Expression and Virus Assembly," Virol. 212:411-421
	67	Zebedee and Lamb (1989) "Growth restriction of influenza A virus by M ₂ protein antibody is genetically linked to the M ₁ protein," Proc Natl Acad Sci USA 86:1061-1065
	68	Pegram and Slamon (2000) "Biological Rationale for HER2/neu (c-erbB2) as a Target for Monoclonal Antibody Therapy," Semin Oncol. 27:13-19
	69	Schenk <i>et al.</i> (1999) "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature 400:173-177
	70	Chang (2000) "The pharmacological basis of anti-IgE therapy," Nat Biotechnol. 18:157-162
	71	Maini and Taylor (2000) "Anti-Cytokine Therapy for Rheumatoid Arthritis," Annu Rev Med. 51:207-229
	72	Chackerian <i>et al.</i> (2001) "Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies," J Clin Invest. 108:415-423
	73	Chackerian <i>et al.</i> (1999) "Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles," Proc Natl Acad Sci USA 96:2373-2378
	74	Tall (1993) "Plasma cholesteryl ester transfer protein," Lipid Res. 34:1255-1274
	75	Barter <i>et al.</i> (1982) "Transfers and exchanges of esterified cholesterol between plasma lipoproteins," Biochem J. 208:1-7
	76	Whitlock <i>et al.</i> (1989) "Monoclonal Antibody Inhibition of Cholesteryl Ester Transfer Protein Activity in the Rabbit," J Clin Invest. 84:129-137
	77	Kothari <i>et al.</i> (1997) "Inhibition of cholesterol ester transfer protein by CGS 25159 and changes in lipoproteins in hamsters," Atherosclerosis 128:59-66

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Separate Sheets if Necessary) (37 CFR § 1.98(b))				Applicant: David R. Milich <i>et al.</i>	
				Filing Date: 07/30/2003	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
mm	78	Sugano and Makino (1996) "Changes in Plasma Lipoprotein Cholesterol Levels by Antisense Oligodeoxynucleotides against Cholesteryl Ester Transfer Protein in Cholesterol-fed Rabbits," J Biol Chem. 271:19080-19083			
	79	Sugano <i>et al.</i> (1998) "Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits," J. Biol. Chem. 273:5033-5036			
	80	Agellon <i>et al.</i> (1991) "Reduced High Density Lipoprotein Cholesterol in Human Cholesteryl Ester Transfer Protein Transgenic Mice," J Biol Chem. 266:10796-10801			
	81	Herrera <i>et al.</i> (1999) "Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein," Nat Med. 5:1383-1389			
	82	Koizumi <i>et al.</i> (1985) "Deficiency of Serum Cholesteryl-Ester Transfer Activity in Patients with Familial Hyperalphalipoproteinaemia," Atherosclerosis 58:175-186			
	83	Rittershaus <i>et al.</i> (2000) "Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis," Arterioscler Thromb Vasc Biol. 20:2106-2112			
	84	Milich <i>et al.</i> (1998) "The Secreted Hepatitis B Precore Antigen Can Modulate the Immune Response to the Nucleocapsid: A Mechanism for Persistence," J. Immunol. 160:2013-2021			
	85	Morgan <i>et al.</i> (2000) "Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," Nature 408:982-985			
	86	Smith <i>et al.</i> (2002) "Predicting the failure of amyloid-β vaccine," Lancet 359:1864-1865			
	87	Hock <i>et al.</i> (2002) "Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease," Nat Med. 8:1270-1275			
	88	McLaurin <i>et al.</i> (2002) "Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis," Nat Med. 8:1263-1269			
	89	Rabjohn <i>et al.</i> (2002) "Modification of Peanut Allergen Ara h 3: Effects on IgE Binding and T Cell Stimulation," Int Arch Allergy Immunol. 128:15-23			
	90	Beezhold <i>et al.</i> (2001) "Mutational analysis of the IgE epitopes in the latex allergen Hev b 5," J Allergy Clin Immunol. 107:1069-1076			
	91	Reese <i>et al.</i> (2001) "Characterization and identification of allergen epitopes: recombinant peptide libraries and synthetic, overlapping peptides," J Chromatogr B Biomed Sci Appl. 756:157-163			
	92	Suphioglu <i>et al.</i> (2001) "A novel grass pollen allergen mimotope identified by phage display peptide library inhibits allergen-human IgE antibody interaction," FEBS Lett. 502:46-52			
	93	Focke <i>et al.</i> (2001) "Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination," FASEB J. 15:2042-2044			
	94	Karpenko, <i>et al.</i> (2000) "Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble," Amino Acids 18:329-337			
	95	Casal <i>et al.</i> (1999) "Parvovirus-Like Particles as Vaccine Vectors," Methods 19:174-186			
	96	Sadeyen <i>et al.</i> (2003) "Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduced their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope," Virology 309:32-40			
	97	Varsani <i>et al.</i> (2003) "Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16," J. Virol., 77:8386-8393			
	98	Rose <i>et al.</i> (1993) "Expression of Human Papillomavirus Type 11 L1 Protein in Insect Cells: In Vivo and In Vitro Assembly of Viruslike Particles," J Virol. 67:1936-1944			
	99	Gedvilaite <i>et al.</i> (2000) "Formation of Immunogenic Virus-like Particles by Inserting Epitopes into Surface-Exposed Regions of Hamster Polyomavirus Major Capsid Protein," Virol. 20:21-35			
	100	Pumpens <i>et al.</i> (2002) "Evaluation of HBs, HBc, and frCP Virus-Like Particles for Expression of Human Papillomavirus 16E7 Oncoprotein Epitopes," Interviol. 45:24-32			
	101	Roth (2000) "The yeast Ty virus-like particles," Yeast 16:785-795			
	102	Wagner <i>et al.</i> (1996) "Safety and Immunogenicity of Recombinant Human Immunodeficiency Virus-Like Particles in Rodents and Rhesus Macaques," Interviol. 39:93-103			
Examiner:			Date Considered:		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: David R. Milich <i>et al.</i>	
(37 CFR § 1.98(b))				Filing Date: 07/30/2003	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
mm	103	Baumert <i>et al.</i> (1999) "Hepatitis C Virus-like Particles Synthesized in Insect Cells as a Potential Vaccine Candidate," Gastroenterology 117:1397-1407			
	104	Sabara <i>et al.</i> (1991) "Assembly of Double-Shelled Rotaviruslike Particles by Simultaneous Expression of Recombinant VP6 and VP7 Proteins," J. Virol. 65:6994-6997			
	105	Ball <i>et al.</i> (1999) "Recombinant Norwalk Virus-like Particles given Orally to Volunteers" Phase I Study," Gastroenterology 117:40-48			
	106	Brown <i>et al.</i> (1991) "Assembly of Empty Capsids by Using Baculovirus Recombinants Expressing Human Parvovirus B19 Structural Proteins," J. Virol. 65:2702-2706			
	107	Thomsen <i>et al.</i> (1994) "Assembly of Herpes Simplex Virus (HSV) Intermediate Capsids in Insect Cells Infected with Recombinant Baculoviruses Expressing HSV Capsid Proteins," J. Virol. 68:2442-2457			
	108	Urakawa <i>et al.</i> (1989) "Synthesis of Immunogenic, but Non-infectious, Poliovirus Particles in Insect Cells by a Baculovirus Expression Vector," J. Gen. Virol. 70:1453-1463			
	109	Brown <i>et al.</i> (2002) "RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation," Intervirology 45:371-380			
	110	French <i>et al.</i> (1990) "Assembly of Double-Shelled, Viruslike Particles of Bluetongue Virus by the Simultaneous Expression of Four Structural Proteins," J. Virol. 64:5695-5700			
	111	Yamshchikov <i>et al.</i> (1995) "Assembly of SIV Virus-like Particles Containing Envelope Proteins Using a Baculovirus Expression System," Virol. 214:50-58			
	112	Plana-Duran <i>et al.</i> "Oral immunization of rabbits with VP60 particles confers protection against rabbit hemorrhagic disease," (1996) Arch. Virol. 141:1423-1436			
	113	Nikura <i>et al.</i> (2002) "Chimeric Recombinant Hepatitis E Virus-like Particles as an Oral Vaccine Vehicle Presenting Foreign Epitopes," Virol. 293:273-280			
	114	Yao (2003) "Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles," Res. Initiat. Treat Action 8:20-21			
	115	Kakker <i>et al.</i> (1999) "Bovine Leukemia Virus Gag Particle Assembly in Insect Cells: Formation of Chimeric Particles by Domain-Switched Leukemia/Lentivirus Gag Polypeptide," Virol. 265:308-318			
	116	Milich <i>et al.</i> (1994) "Extrathymic Expression of the Intracellular Hepatitis B Core Antigen Results in T Cell Tolerance in Transgenic Mice," J. Immunol. 152:455-466			
	117	Milich and McLachlan (1986) "The Nucleocapsid of Hepatitis B Virus Is Both a T-Cell-Independent and a T-Cell-Dependent Antigen," Science 234:1398-1401			
	118	Takashi <i>et al.</i> (1983) "Immunochemical Structure of Hepatitis B e Antigen in the Serum," J Immunol. 130:2903-2911			
	119	Ferrari <i>et al.</i> (1990) "Cellular Immune Response to Hepatitis B Virus-Encoded Antigens in Acute and Chronic Hepatitis B Virus Infection," J Immunol. 145:3442-3449			
	120	Milich <i>et al.</i> (1990) "Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance <i>in utero</i> ," Proc. Natl. Acad. Sci. USA 87:6599-6603			
	121	Calvo-Calle <i>et al.</i> (1997) "Binding of Malaria T Cell Epitopes to DR and DQ Molecules In Vitro Correlates with Immunogenicity In Vivo," J Immunol. 159:1362-1373			
	122	Genbank Accession No. NP_671816 printed 8/3/93			
	123	Genbank Accession No. NKVLC printed 7/16/99			
	124	Genbank Accession No. NP_043683 printed 12/10/02			
	125	Heterobifunctional Cross-linkers, Pierce Chemical Technical Library			
	126	Milich <i>et al.</i> (2002) "Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate," Vaccine 20:771-788			
	127	Wynne <i>et al.</i> (1999) "The Crystal Structure of the Human Hepatitis B Virus Capsid," Mol. Cell. 3:771-780			
Examiner:			Date Considered:		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Separate Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: David R. Milich <i>et al.</i>	
				Filing Date: 07/30/2003	Group Art Unit:
mm	128	Hollinger and Dienstag, Chapter 82, Hepatitis B and D Viruses, in <i>Manual of Clinical Microbiology</i> , 7th ed., ASM Press, Washington, D.C., 1999			
I	129	Dubovsky, "Creating a Vaccine against Malaria," The Maralaria Vaccine Initiative, PATH (Program for Appropriate Technology in Health), January 2001			
I	130	Falciparum Malaria MSP1 Workshop, Progress toward MSP1 Vaccine Development and Testing, The Maralaria Vaccine Initiative, PATH (Program for Appropriate Technology in Health), December 2000			
I	131	Lu <i>et al.</i> (1999) "Immunization of Woodchucks with Plasmids Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen and Surface Antigen Suppresses WHV Infection," J. Virol. 73:281-289			
I	132	Menne <i>et al.</i> (1997) "Characterization of T-Cell Response to Woodchuck Hepatitis Virus Core Protein and Protection of Woodchucks from Infection by Immunization with Peptides Containing a T-Cell Epitope," J. Virol. 71:65-74			
I	133	Lew <i>et al.</i> (2001) "In Vitro and In Vivo Infectivity and Pathogenicity of the Lymphoid Cell-Derived Woodchuck Hepatitis Virus," J. Virol. 75:1770-1782			
I	134	Siegel <i>et al.</i> (2001) "Coadministration of Gamma Interferon with DNA Vaccine Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen Enhances the Specific Immune Response and Protects against WHV Infection," J. Virol. 75:5036-5042			
I	135	Birkett, U.S. Patent Application No. 09/930,915, filed: August 15, 2001, published July 24, 2003 as Publication No. 20030138769, and entitled "Immunogenic HBc chimer particles having enhanced stability			
I	136	Brown <i>et al.</i> , U.S. patent publication No. US 20030175296 published Sept. 18, 2003.			
Examiner: m. m. f. p. w.		Date Considered: Dec. 03, 2004			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					